ArticleInternational journal of molecular medicine2026
Molecular mechanism of hydromorphone preconditioning in cerebral ischemia/reperfusion‑induced inflammatory injury.
Article in International journal of molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study explored the protective mechanism of hydromorphone (HM) preconditioning in cerebral ischemia/reperfusion injury (CIRI). An animal model of CIRI was established by middle cerebral artery occlusion/reperfusion in male C57BL/6J mice. An I/R cell model was induced by oxygen‑glucose deprivation/reperfusion. Brain tissue injury and cell injury were evaluated by hematoxylin and eosin staining, 2,3,5‑triphenyltetrazolium chloride staining, lactate dehydrogenase testing and a Cell Counting Kit‑8 assay. Nod‑like receptor protein 3 (NLRP3)‑positive expression and caspase‑1 activity were assessed by immunostaining and caspase‑1 activity assays, respectively. Reverse transcription‑quantitative PCR or western blotting were used to quantify the expression levels of microRNA (miR)‑195‑5p, RNA‑binding motif protein 15 (RBM15) and upstream stimulatory factor 2 (USF2). RNA immunoprecipitation (RIP) and dual‑luciferase assays verified the binding between miR‑195‑5p and RBM15, followed by RIP analysis of N6‑methyladenosine (m6A) enrichment on USF2 and quantitative analysis of m6A content. The binding of RBM15 and insulin‑like growth factor 2 mRNA‑binding protein 3 (IGF2BP3) to the USF2 m6A site was analyzed by a dual‑luciferase assay. HM preconditioning inhibited NLRP3‑mediated pyroptosis, alleviated neurological deficits, and reduced inflammatory injury in brain tissue. Mechanistically, hydromorphone (HM) preconditioning targeted RBM15 and reduced IGF2BP3‑mediated m6A modification by upregulating miR‑195‑5p expression, thus decreasing USF2 expression, reducing the enrichment of USF2 on the NLRP3 promoter, and inhibiting NLRP3‑mediated pyroptosis. In conclusion, HM preconditioning may repress NLRP3‑mediated pyroptosis and alleviate CIRI via the effects of miR‑195‑5p/RBM15/USF2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.